genuine question about sequence that I am slightly embarrassed to ask
genuine question about sequence that I am slightly embarrassed to ask. I would rather ask a basic question now than get this wrong quietly for two months. Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is…
ask for the mass spectrum, not just the purity number
preclinical enthusiasm is not clinical evidence
preclinical enthusiasm is not clinical evidence
Adding the standing caveat — research material is not approved for human use, wherever you are.
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
stability in solution is the practical question nobody asks
Which paper is that claim from, and was it in humans?
Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.
This. Mass spectrometry for identity, not just an area percent, because a pure something-else is still something else.
Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.